Healthcare Global Enterprises Limited has informed the Exchange about Investor Presentation
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
HCG reported strong FY26 results with revenue of INR 25,454 Mn (+15% YoY) and adjusted EBITDA of INR 4,711 Mn (+19% YoY). EBITDA margin expanded 68 basis points to 18.5%, demonstrating consistent margin improvement trajectory. Q4FY26 revenue grew 11% YoY to INR 6,523 Mn with EBITDA margin at 19.2%. The company completed a rights issue raising INR 4,250 Mn (oversubscribed 1.3x) and de-levered its balance sheet with Net Debt/EBITDA improving to 1.43x from 2.27x. Key strategic move includes divestment of non-core fertility business (Milann) to Inviga Healthcare Fund I for INR 376 Mn equity consideration, expected to close in Q1 FY27. North Bangalore facility with MR-LINAC technology has commenced operations. Regional growth was broad-based with West (+13%), South (+9%), and East (+8%) contributing to overall performance.
HCG's margin expansion and balance sheet de-leveraging signal improving operational efficiency and financial health. The Milann divestment will sharpen focus on core oncology business and unlock capital for growth. Rights issue proceeds provide flexibility for expansion investments while maintaining a healthy leverage profile.